Revitope Oncology Inc. announced that it has signed a license agreement providing Genmab A/S (Genmab) access to Revitope's conditional TCE technology, TwoGATE™. Genmab is granted exclusive rights to utilize TwoGate™ for multiple drug target pairs during a multi-year research period, including the option to take up to three exclusive licenses for worldwide development and commercialization of the resulting products.
TwoGATE™ leverages the dual antigen binding requirement of a unique split paratope that assembles on the tumor cell surface to potently engage T cells with high precision, potentially addressing key areas of unmet need in the treatment of solid tumors.
"The unique blending of precision protein engineering in TwoGATE™ with target pairs that are exquisitely tailored to solid tumors with high unmet need, offers the potential to transform treatment of solid tumors by allowing TCEs to be dosed at levels that achieve significant efficacy without inducing systemic toxicities," said Werner Meier, Chief Scientific Officer of Revitope. "Genmab is the ideal partner to bring this potential to patients.
"We are thrilled to partner with Genmab, a leading biotechnology company," said Mark Clement, Chief Operating Officer of Revitope. "In deploying our cutting-edge TwoGATE™ technology platform together with Genmab's robust antibody engineering and development capabilities, Revitope aims to strengthen Genmab's pipeline, thereby aiding the transformation of cancer treatment."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!